{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000020","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.622481+00:00","generated_at":"2026-05-23T12:48:08.869873+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand subsidiary Pelthos to merge with Channel Therapeutics; $50M capital raise","bullets":["Channel to acquire 100% of Pelthos; combined company renamed Pelthos Therapeutics, listing as PTHS on NYSE American.","Total $50M equity raised: $18M from Ligand, $32M from Murchinson-led investor group.","Ligand retains 13% royalty on worldwide sales of ZELSUVMI, FDA-approved for Molluscum contagiosum.","Scott Plesha to become CEO, Frank Knuettel CFO; board includes two Ligand appointees.","Transaction expected to close summer 2025, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000020","json":"https://secwatch.observer/filing/0000886163-25-000020.json","markdown":"https://secwatch.observer/filing/0000886163-25-000020.md","text":"https://secwatch.observer/filing/0000886163-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/0000886163-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/lgnd-20250416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T12:48:08.869873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}